An Open-label Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 09 May 2019
Price : $35 *
At a glance
- Drugs CYAD 01 (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions
- Acronyms LINK
- Sponsors Celyad
- 07 May 2019 Planned End Date changed from 1 Jul 2020 to 15 Dec 2019.
- 07 May 2019 Status changed from recruiting to active, no longer recruiting.
- 29 Mar 2018 According to a Celyad media release, results from this study will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2018.